Boehringer Ingelheim expands with Shanghai research and development center

Executives open the new Boehringer Ingelheim Asian Veterinary Research & Development Center in Zhangjiang, Shanghai. 

Pharmaceutical company Boehringer Ingelheim is expanding its animal health business with its first research and development center in China, opening the Asian Veterinary Research & Development Center in Zhangjiang, Shanghai.
Boehringer has invested €12 million into the 1,900-square-meter center, which creates 70 new scientific workplaces in the area and will bring new bio-research technologies to the country. “Boehringer Ingelheim’s long-term focus is to further strengthen its very strong global position in the animal health business, particularly in the vaccine segment," said Hubertus von Baumbach, responsible for the corporate board divisions of finance and animal health.
The center is positioned to identify and develop vaccines against livestock diseases focusing on China and the Asian markets.